Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis

Toxicology and Applied Pharmacology

Volumn 258, Issue 2, 2012, Pages 296-308

  Das, Joydeep ^a   Vasan, Vandana ^a   Sil, Parames C ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Akt; Alloxan induced diabetes; Apoptosis; Cytokines; GLUT4; Heart; Hyperglycemia; Insulin receptor; Taurine

Indexed keywords

CASPASE 3; CASPASE 9; CATALASE; CHOLESTEROL; GENOMIC DNA; GLUCOSE; GLUCOSE TRANSPORTER 4; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MYELOPEROXIDASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAURINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; XANTHINE OXIDASE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC CARDIOMYOPATHY; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART INJURY; HEART MUSCLE FIBER MEMBRANE; HEART PROTECTION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PANCREAS INJURY; PROTEIN CARBONYLATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; UPREGULATION; WEIGHT REDUCTION;

ALLOXAN; ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HEART; INSULIN; LIPIDS; MALE; NF-KAPPA B; OXIDATIVE STRESS; PROTEIN TRANSPORT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TAURINE;

ANIMALIA; RATTUS;

EID: 84855759890     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.11.009     Document Type: Article

References (91)

1. Aerts L., Van Assche F.A. Taurine and taurine-deficiency in the perinatal period. J. Perinat. Med. 2002, 30:281-286.
2. Akhileshwar V., Patel S.P., Katyare S.S. Diabetic cardiomyopathy and reactive oxygen species (ROS) related parameters in male and female rats: a comparative study. Ind. J. Clin. Biochem. 2007, 22:84-90.
3. Alvarado-Vasquez N., Zamudio P., Ceron E., Vanda B., Zenteno E., Carvajal-Sandoval G. Effect of glycine in streptozotocin induced diabetic rats. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2003, 134:521-527.
4. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Siedman, J.G., Smith, J.A., Struhl, K. (Eds.), 2003. Current Protocols in Molecular Biology. In: Albright, L.M., Coen, D.M., Varki, A. (Guest Eds.), John Wiley and Sons, Inc.
5. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
6. Bergmeyer H.U., Gawehn K., Grassl M. Methods of Enzymatic Analysis 1974, vol. I:521-522. Academic Press Inc., New York, NY. Second ed. H.U. Bergmeyer (Ed.).
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
8. Brons C., Spohr C., Storgaard H., Dyerberg J., Vaag A. Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur. J. Clin. Nutr. 2004, 58:1239-1247.
9. Brosnan J.T., Brosnan M.E. The sulfur-containing amino acids: an overview. J. Nutr. 2006, 136. 1636Se1640S.
10. Brownsey R.W., Boone A.N., Allard M.F. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc. Res. 1997, 34:3-24.
11. Bryant N.J., Govers R., James D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 2002, 3:267-277.
12. Carneiroa E.M., Latorracab M.Q., Araujoc E., Beltrad M., Oliverase M.J., Navarro M., Berna G., Bedoya F.J., Vellosoc L.A., Soria B., Martin F. Taurine supplementation modulates glucose homeostasis and islet function. J. Nutr. Biochem. 2009, 20:503-511.
13. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2000, 49:27-29.
14. Chang K.J., Kwon W. Immunohistochemical localization of insulin in pancreatic beta-cells of taurine-supplemented or taurine-depleted diabetic rats. Adv. Exp. Med. Biol. 2000, 483:579-587.
15. Chang L., Xu J., Yu F., Zhao J., Tang X., Tang C.S. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004, 27:37-48.
16. Charron M.J., Katz E.B., Oslon A.L. GLUT4 gene regulation and manipulation. J. Biol. Chem. 1999, 274:3253-3256.
17. Chatterjea M.N., Shinde R. Text Book of Medical Biochemistry 2002, 317. Jaypee Brothers, Medical Publishers, Ltd., New Delhi. 5th ed.
18. Cherif H., Reusens B., Ahn M.T., Hoet J.J., Remacle C. Effects of taurine on the insulin secretion of rat fetal islets from dams fed a low-protein diet. J. Endocrinol. 1998, 159:341-348.
19. Colivicchi M.A., Raimondi L., Bianchi L., Tipton K.F., Pirisino R., Della Corte L. Taurine prevents streptozotocin impairment of hormone-stimulated glucose uptake in rat adipocytes. Eur. J. Pharmacol. 2004, 495:209-215.
20. Cos P., Ying L., Calomme M., Hu J.P., Cimanga K., Van Poel B., et al. Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and superoxide scavengers. J. Nat. Prod. 1998, 61:71-76.
21. Das J., Ghosh J., Manna P.M., Sil P.C. Taurine provides antioxidant defense against NaF-induced cytotoxicity in murine hepatocytes. Pathophysiology 2008, 15:181-190.
22. Das J., Ghosh J., Manna P., Sinha M., Sil P.C. Taurine protects rat testes against NaAsO2-induced oxidative stress and apoptosis via mitochondrial dependent and independent pathways. Toxicol. Lett. 2009, 187:201-210.
23. Das J., Ghosh J., Manna P., Sinha M., Sil P.C. Arsenic-induced oxidative cerebral disorders: protection by taurine. Drug Chem. Toxicol. 2009, 32:93-102.
24. Das J., Ghosh J., Manna P., Sil P.C. Taurine protects acetaminophen-induced oxidative damage in mice kidney through APAP urinary excretion and CYP2E1 inactivation. Toxicology 2010, 269:24-34.
25. Das J., Ghosh J., Manna P., Sil P.C. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free. Radic. Res. 2010, 44:340-355.
26. Das J., Ghosh J., Manna P., Sil P.C. Protective role of taurine against arsenic-induced mitochondria-dependent hepatic apoptosis via the inhibition of PKCdelta-JNK pathway. PLoS One 2010, 5:e12602.
27. Das J., Ghosh J., Manna P., Sil P.C. Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNK. Biochem. Pharmacol. 2011, 81:891-909.
28. Das J., Ghosh J., Manna P., Sil P.C. Taurine protects rat testes against doxorubicin-induced oxidative stress as well as p53, Fas and caspase12-mediated apoptosis. Amino Acids 2011, 10.1007/s00726-011-0904-4.
29. De la Puerta C., Arrieta F.J., Balsa J.A., Botella-Carretero J.I., Zamarron I., Vazquez C. Taurine and glucose metabolism: a review. Nutr. Hosp. 2010, 25:910-919.
30. Di Leo M.A., Santini S.A., Silveri N.G., Giardina B., Franconi F., Ghirlanda G. Long-term taurine supplementation reduces mortality rate in streptozotocin-induced diabetic rats. Amino Acids 2004, 27:187-191.
31. Ekelund U.E., Harrison R.W., Shokek O., Thakkar R.N., Tunin R.S., Senzaki H., Kass D.A., Marban E., Hare J.M. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. 1999, 85:437-445.
32. Elizarova E.P., Nedosugova L.V. First experiments in taurine administration for diabetes mellitus. The effect on erythrocyte membranes. Adv. Exp. Med. Biol. 1996, 403:583-588.
33. El-Seweidy M.M., Sadik N.A.H., Shaker O.G. Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats. Arch. Biochem. Biophys. 2011, 506:48-57.
34. Gavrovskaya L.K., Ryzhova O.V., Safonova A.F., Matveev A.K., Sapronov N.S. Protective effect of taurine on rats with experimental insulin-dependent diabetes mellitus. Bull. Exp. Biol. Med. 2008, 146:226-228.
35. Ghosh J., Das J., Manna P., Sil P.C. Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: role of NF-kappa B, p38 and JNK MAPK pathway. Toxicol. Appl. Pharmacol. 2009, 240:73-87.
36. Giardino I., Fard A.K., Hatchell D.L., Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998, 47:1114-1120.
37. Giri S.N., Gurujeyalakshmi G., Wang Y. Suppression of bleomycin-induced increased production of nitric oxide and NF-kB activation by treatment with taurine and niacin. Adv. Exp. Med. Biol. 2000, 483:545-561.
38. Gurujeyalashmi G., Wang Y., Giri S.N. Taurine and niacin block lung and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kB in mice. J. Pharmacol. Exp. Ther. 2000, 293:82-90.
39. Gylling H., Miettinen T.A. Cholesterol absorption, synthesis and low and high density lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Diabetes Care 1997, 20:90-95.
40. Haruta T., Morris A.J., Rose D.W., Nelson J.G., et al. Insulin-stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. J. Biol. Chem. 1995, 270:27991-27994.
41. Howard-Alpe G.M., Sear J.W., Foex P. Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers. Br. J. Anaesth. 2006, 97:758-769.
42. Huisamen B., van Zyl M., Keyser A., Lochner A. The effects of insulin and β-adrenergic stimulation on glucose transport, glut 4 and PKB activation in the myocardium of lean and obese non-insulin dependent diabetes mellitus rats. Mol. Cell. Biochem. 2001, 223:15-25.
43. Jang Y.M., Kendaiah S., Drew B., Phillips T., Selman C., Julian D., Leeuwenburgh C. Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett. 2004, 577:483-490.
44. Kain V., Kumar S., Puranik A.S., Sitasawad S.L. Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc. Diabetol. 2010, 9:82.
45. Kaplan B., Karabay G., Zagyapan R.D., Ozer C., Sayan H., Duyar I. Effect of taurine in glucose and taurine administration. Amino Acids 2004, 27:327-333.
46. Kim H.W., Lee A.J., You S., Park T., Lee D.H. Characterization of taurine as inhibitor of sodium glucose transporter. Adv. Exp. Med. Biol. 2006, 583. 137e145.
47. Kontny E., Szczepanska K., Kowalczewski J., Kurowska M., Janicka I., Marcinkiewicz J., et al. The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum. 2000, 43:2169-2177.
48. Kuhad A., Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 2009, 84:296-301.
49. Kulakowski E.C., Maturo J. Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem. Pharmacol. 1984, 33:2835-2838.
50. Lehto S., Niskanen L., Ronnemaa T., Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998, 29:635-639.
51. Li F., Obrosova I.G., Abatan O., Tian D., Larkin D., Stuenkel E.L., Stevens M.J. Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of STZ-D rats. Am. J. Physiol. Endocrinol. Metab. 2005, 288. E29eE36.
52. Lizotte E., Grandy S.A., Tremblay A., Allen B.G., Fiset C. Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. Cell. Physiol. Biochem. 2009, 23:75-86.
53. Manna P., Sinha M., Sil P.C. Taurine triggers a chemoprevention against cadmium induced testicular oxidative injury. Reprod. Toxicol. 2008, 26:282-291.
54. Manna P., Sinha M., Sil P.C. Amelioration of cadmium-induced cardiac impairment by taurine. Chem. Biol. Interact. 2008, 174:88-97.
55. Manna P., Sinha M., Sil P.C. Taurine plays a beneficial role against cadmium-induced oxidative renal dysfunction. Amino Acids 2009, 36:417-428.
56. Manna P., Ghosh J., Das J., Sil P.C. Streptozotocin induced activation of oxidative stress responsive splenic cell signaling pathways: protective role of arjunolic acid. Toxicol. Appl. Pharmacol. 2010, 244:114-129.
57. Manna P., Das J., Ghosh J., Sil P.C. Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: prophylactic role of arjunolic acid. Free Radic. Biol. Med. 2010, 48:1465-1484.
58. Maturo J., Kulakowski E.C. Taurine binding to the purified insulin receptor. Biochem. Pharmacol. 1988, 37:3755-3760.
59. Murakami K., Shigematsu Y., Hamada M., Higaki J. Insulin resistance in patients with hypertrophic cardiomyopathy. Circ. J. 2004, 68:650-655.
60. Naito Y., Yoshikawa T., Matsuyama K., Yagi N., Arai M., Nakamura Y., et al. Neutrophils, lipid peroxidation, and nitric oxide in gastric reperfusion injury in rats. Free Radic. Biol. Med. 1998, 24:494-502.
61. Nakaya Y., Minami A., Harada N., Sakamoto S., Niwa Y., Ohnaka M. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneously type 2 diabetes. Am. J. Clin. Nutr. 2000, 71:54-58.
62. Nandhini A.T., Thirunavukkarasu V., Anuradha C.V. Stimulation of glucose utilization and inhibition of protein glycation and AGE products by taurine. Acta Physiol. Scand. 2004, 181. 297e303.
63. Nizamutdinova I.T., Jin Y.C., Chung J., Shin S.C., Lee S.J., Seo H.G., Lee J.H., Chang K.C., Kim H.J. The anti-diabetic effect of anthocyanins in streptozotocin-induced diabetic rats through glucose transporter 4 regulation and prevention of insulin resistance and pancreatic apoptosis. Mol. Nutr. Food Res. 2009, 53:1419-1429.
64. Obrosova I.G., Minchenko A.G., Marinescu V., Fathallah L., Kennedy A., Stockert C.M., Frank R.N., Stevens M.J. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001, 44. 1102e1110.
65. Pandya K.G., Patel M.R., Lau-Cam C.A. Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide. J. Biomed. Sci. 2010, 17(Suppl. 1):S16.
66. Pessin J.E., Thurmond D.C., Elmendorf J.S., Coker K.J., Okada S. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location!. J. Biol. Chem. 1999, 274:2593-2596.
67. Racasan S., Braam B., van der Giezen D.M., Goldschmeding R., Boer P., Koomans H.A. Perinatal l-arginine and antioxidant supplements reduce adult blood pressure in spontaneously hypertensive rats. Hypertension 2004, 44:83-88.
68. Rodrigues B., McNeill J.H. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc. Res. 1992, 26:913-922.
69. Roy S., Dontamalla S.K., Mondru A.K., Sannigrahi S., Reddy Veerareddy P. Downregulation of apoptosis and modulation of TGF-β1 by sodium selenate prevents streptozotocin-induced diabetic rat renal impairment. Biol. Trace Elem. Res. 2011, 139:55-71.
70. Schuller-Levis G.B., Park E. Taurine: new implications for an old amino acid. FEMS Microbiol. Lett. 2003, 226:195-202.
71. Shih K.C., Kwak C.F., Hwa C.M. Acipimox attenuates hypertriglyceredemia in dislipidemic non-insulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control. Diab. Res. Clin. Pract. 1997, 36:113-119.
72. Sinha M., Manna P., Sil P.C. Taurine, a conditionally essential amino acid, ameliorates arsenic-induced cytotoxicity in murine hepatocytes. Toxicol. In Vitro 2007, 21:1419-1428.
73. Sinha M., Manna P., Sil P.C. Taurine protects antioxidant defense system in the erythrocytes of cadmium treated mice. BMB Rep. 2008, 41:657-663.
74. Sinha M., Manna P., Sil P.C. Cadmium induced neurological disorders: prophylactic role of taurine. J. Appl. Toxicol. 2008, 28:974-986.
75. Stamler J., Stamler R., Brown W.V., Gotto A.M., Greenland P., et al. Serum cholesterol. Doing the right thing. Circulation 1993, 88:1954-1960.
76. Sun D., Shen M., Li J., Li W., Zhang Y., Zhao L., Zhang Z., Yuan Y., Wang H., Cao F. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3b dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc. Diabetol. 2011, 10:4.
77. Suryawanshi N.P., Bhutey A.K., Nagdeote A.N., Jadhav A.A., Manoorkar G.S. Study of lipid peroxide and lipid profile in diabetes mellitus. Ind. J. Clin. Biochem. 2006, 21:126-130.
78. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001, 50:536-546.
79. Thomson M.J., Puntmann V., Kaski J.C. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment?. Cardiovasc. Drugs Ther. 2007, 21:195-210.
80. Tokunaga H., Yoneda Y., Kuriyama K. Streptozotocin-induced elevation of pancreatic taurine content and suppressive effect of taurine on insulin secretion. Eur. J. Pharmacol. 1983, 87:237-243.
81. Vasqueza N.A., Zamudioa P., Cerona E., Vandab B., Zentenoc E., Sandovala G.C. Effect of glycine in streptozotocin-induced diabetic rats. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2003, 134:521-527.
82. Verma L., Singour P.K., Chaurasiya P.K., Rajak H., Pawar R.S., Patil U.K. Effect of ethanolic extract of Cassia occidentalis Linn. for the management of alloxan-induced diabetic rats. Pharmacognosy Res. 2010, 2:132-137.
83. Winiarska K., Szymanski K., Gorniak P., Dudziak M., Bryla J. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 2009, 91. 261e270.
84. Winterbourn C.C., Vissers M.C., Kettle A.J. Myeloperoxidase. Curr. Opin. Hematol. 2000, 7:53-58.
85. Wolff S.P., Dean R.T. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem. J. 1987, 245:243-250.
86. Wu N., Lu Y., He B., Zhang Y., Lin J., Zhao S., Zhang W., Li Y., Han P. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhibiting JNK1 activation and improving insulin signaling in vivo. Diab. Res. Clin. Pract. 2010, 90:288-296.
87. Yao H.T., Lin P.P., Chang Y.W., Chen C.T., Chiang M.T., Chang L., Kuo Y.C., Tsai H.T., Yeh T.K. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and kidneys of rats with streptozotocin-induced diabetes. Food Chem. Toxicol. 2009, 47:1703-1709.
88. Yeh C.H., Sturgis L., Haidacher J., Zhang X.N., Sherwood S.J., Bjercke R.J., Juhasz O., Crow M.T., Tilton R.G., Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504.
89. Yim S., Malhotra A., Veves A. Antioxidants and CVD in diabetes: where do we stand now?. Curr. Diab. Rep. 2007, 7:8-13.
90. Yokogoshi H., Mochizuki H., Nanami K., Hida Y., Miyahi F., Oda H. Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J. Nutr. 1999, 129:1705-1712.
91. Zhou R., Xu Q., Zheng P., Yan L., Zheng J., Dai G. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur. J. Pharmacol. 2008, 586:244-250.